These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, report not yet due 2015-002380-42 Phase 3 Randomized trial of carfilzomib, lenalidomide, dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma. Randomizowane badanie kliniczne fazy 3, porównujące z... 2024-11-21 not-yet-due
Completed, report not yet due 2016-005053-20 A multicenter, single-arm, phase II study to evaluate a safety and efficacy of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed/refractory Waldenström Macroglobuline... 2024-04-30 not-yet-due
Other 2017-003253-41 PRE-emptive DAratumumab Therapy Of minimal Residual disease reappearance or biochemical relapse in multiple myeloma (PREDATOR). Prewencyjna terapia Daratumumabem nawrotu minimalnej choroby resztkow... not-yet-due
Other 2018-004031-68 A Randomized, Open-label Phase 3 Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma... not-yet-due